DeepSeek says it can match or best the performance of models from U.S. firms like Sam Altman’s OpenAI at a fraction of the cost. © 2025 Fortune Media IP Limited ...
CLEVELAND, Ohio — For people with Type 1 diabetes, life is penny-pinching to afford life-saving insulin, scrambling to book medical appointments and fighting to get health insurance to pay up ...
Obesity-focused Aardvark Therapeutics is hoping to raise $100 million in an initial public offering (IPO), according to a US Securities and Exchange Commission (SEC) filing. The Californian biopharma ...
No mercy, no quarter, no hesitation. Two ideologies walk into the Thunderdome, and one walks out. There used to be norms, and then the Democrats decided not to honor the norms but demanded that we ...
Obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) has filed for a $100M initial public offering. Aardvark (NASDAQ:AARD) didn't disclose any terms in its SEC filing, but indicated in its ...
The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins ...
The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut. In a 2025 punctuated by news from the weight-loss space, obesity-focused biotech ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈